Lianpeng Chang

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index2.4kcitations106works0.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(75), Lung Cancer Treatments and Mutations(50), Colorectal Cancer Treatments and Studies(17), Genetic factors in colorectal cancer(15), Gastric Cancer Management and Outcomes(12)

Publications106 total

DNA methylation mediates the immunosuppressive tumour microenvironment in metastatic endometrial clear cell carcinoma

EBioMedicine·2025Open Access

KiVi: Kinesthetic-Visuospatial Integration for Dynamic and Safe Egocentric Legged Locomotion

arXiv (Cornell University)·2025Open Access

11 cited

Gastric Cancer·2023· 11 citedOpen Access

Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes

iScience·2023Open Access

Figure S1, Table S1, Table S2 from KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

2023Open Access

Figure S1, Table S1, Table S2 from KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

2023Open Access

Data from KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

2023Open Access

Data from KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

2023Open Access

Data from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

2023Open Access

Figure S1 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

Figure S1 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

Data from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

2023Open Access

Figure S4 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

Supplementary Data and Figures from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

2023Open Access

Table S3 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

Table S1 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

Table S3 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

Data from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

Table S4 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

Figure S3 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

2023Open Access

page 1 of 6Next →

Frequent Co-authors

Yanfang Guan(31), Xuefeng Xia(18), Xin Yi(11), Xin Yi(9), Xin Yi(9), Ling Yang(8), Jianjun Zhang(7), Xuefeng Xia(7), Yaping Xu(6), Lifeng Li(6), Zongbi Yi(6), Binghe Xu(6), Yuhua Gong(5), Yuting Yi(5), John V. Heymach(5), P. Andrew Futreal(5), Fei Ma(5), Xiuwen Guan(5), Pansong Li(5), Jin Li(5)